Diabetic peripheral neuropathy and the management of diabetic peripheral neuropathic pain

Postgraduate Medicine

Volumn 124, Issue 4, 2012, Pages 145-153

  Morales Vidal, Sarkis ^a   Morgan, Christopher ^a   Mccoyd, Mathew ^a   Hornik, Alejandro ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diabetes; Diabetic peripheral neuropathy; Diabetic polyneuropathy; Neuropathic pain

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BENFOTIAMINE; CAPSAICIN; CARBAMAZEPINE; CITALOPRAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULOXETINE; FLUOXETINE; GABAPENTIN; GROWTH FACTOR; LIDOCAINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NORTRIPTYLINE; OPIATE DERIVATIVE; OXYCODONE; PAROXETINE; PLACEBO; PREGABALIN; RUBOXISTAURIN; THIOCTIC ACID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANTICHOLINERGIC SYNDROME; ARTICLE; AUTONOMIC DYSFUNCTION; BEDTIME DOSAGE; BLADDER DYSFUNCTION; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL FEATURE; CONSTIPATION; DIABETIC NEUROPATHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; ERECTILE DYSFUNCTION; FEMALE SEXUAL DYSFUNCTION; HUMAN; LIVER TOXICITY; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRACTICE GUIDELINE; SENSORY NEUROPATHY; SOMNOLENCE; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA; ANALGESIA; DISEASE MANAGEMENT; METHODOLOGY; PERIPHERAL NEUROPATHY; REVIEW;

DIABETIC NEUROPATHIES; DISEASE MANAGEMENT; HUMANS; PAIN MANAGEMENT; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84871692311     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.07.2576     Document Type: Article

References (52)

1. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007;8(suppl 2):S50-S62.
2. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007;335(7610):87.
3. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817-824.
4. Tesfaye S, Chaturvedi N, Eaton SE, et al. EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341-350.
5. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. 1997;46(suppl 2):S54-A57.
6. Dyck PJ, Davies JL, Clark VM, et al. Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care. 2006;29(10):2282-2288.
7. Aring AM, Jones DE, Falko JM. Evaluation and prevention of diabetic neuropathy. Am Fam Physician. 2005;71(11):2123-2128.
8. Tesfaye S, Boulton AJ, Dyck PJ, et al; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-2293.
9. Dyck PJ, Albers JW, Andersen H, et al; on behalf of the Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity [published online ahead of print June 21, 2011]. Diabetes Metab Res Rev.
10. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-1579.
11. Vinik AI, Mehrabyan A. Diagnosis and management of diabetic autonomic neuropathy. Compr Ther. 2003;29(2-3):130-145.
12. Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care. 2004;27(12):2942-2947.
13. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115(3):387-397.
14. Assessment: clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1996;46(3):873-880.
15. Shakher J, Stevens MJ. Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes. 2011;4:289-305.
16. Frykberg RG, Armstrong DG, Giurini J, et al. American College of Foot and Ankle Surgeons. Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. J Foot Ankle Surg. 2000;39(5 suppl):S1-S60.
17. Freeman R. Autonomic peripheral neuropathy. Lancet. 2005; 365(9466):1259-1270.
18. Tentolouris N, Marinou K, Kokotis P, Karanti A, Diakoumopoulou E, Katsilambros N. Sudomotor dysfunction is associated with foot ulceration in diabetes. Diabet Med. 2009;26(3):302-305.
19. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24(7):1264-1269.
20. Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc. 1993;68(7):691-702.
21. Hill SR, Fayyad AM, Jones GR. Diabetes mellitus and female lower urinary tract symptoms: a review. Neurourol Urodyn. 2008;27(5):362-367.
22. Minhas S, Eardley I. Diabetes mellitus and impotence. In: Carson CC 3rd, Kirby RS, Goldstein I, Wyllie MG, eds. Textbook of Erectile Dysfunction. Oxford, England: Isis Medical Media; 1999:541-550.
23. Várkonyi T, Kempler P. Erectile dysfunction. In: Sinclair A, ed. Diabetes in Old Age. Vol 3. New York, NY: John Wiley and Sons; 2009: 149-164.
24. Fraser DM, Campbell IW, Ewing DJ, Clarke BF Mononeuropathy in diabetes mellitus. Diabetes. 1979;28(2):96-101.
25. Boulton AJ, Vinik AI, Arezzo JC, et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956-962.
26. Tamburin S, Zanette G. Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy. Pain Med. 2009;10(8):1476-1480.
27. Asbury AK. Proximal diabetic neuropathy. Ann Neurol. 1977;2(3): 179-180.
28. Vinik A, Mehrabyan A, Colen L, Boulton A. Focal entrapment neuropathies in diabetes. Diabetes Care. 2004;27(7):1783-1788.
29. Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care. 2006;29(4):883-887.
30. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630-1635.
31. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999;16(12):1040-1043.
32. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114-121.
33. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425-1433.
34. Vinik AI, Bril V Kempler P, et al; MBBQ Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther. 2005;27(8):1164-1180.
35. Hotta N, Toyota T, Matsuoka K, et al; SNK-860 Diabetic Neuropathy Study Group. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001;24(10):1776-1782.
36. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-2370.
37. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81(4 suppl):S12-S25.
38. Lindsay TJ, Rodgers BC, Savath V Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician. 2010;82(2):151-158.
39. Diabetic peripheral neuropathic pain. Consensus guidelines for treatment. J Fam Pract. 2006;(suppl):3-19.
40. Obrosova IG, Drel VR, Pacher P, et al. Oxidative-nitrosative stress and poly (ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes. 2005;54(12):3435-3441.
41. Apfel SC, Asbury AK, Bril V, et al. Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci. 2001;189(1-2):3-5.
42. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27(6):1458-1486.
43. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol. 2004;11(3):153-162.
44. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;(4):CD005454.
45. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 suppl):S3-S14.
46. Pape C, Haltenhof H. Tricyclic antidepressants in depressed patients with cardiovascular diseases: a contraindication [in German]? Psychi-atr Prax. 1995;22(1):9-14.
47. Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJ. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care. 2007;30(1):21-26.
48. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
49. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis. 2001;3(2):53-62.
50. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houldren RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374(9697):1252-1261.
51. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. CMRO. 2009;25(7):1677-1687.
52. Selph S, Carson S, Fu R, Thakurta S, Low A, McDonagh M. Drug Class Review: Neuropathic Pain. Final Update 1 Report. Drug Class Reviews. Portland, OR: Oregon Health and Science University; 2011.